WO2010020675A1
(en)
|
2008-08-22 |
2010-02-25 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
UY33226A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
JP5918214B2
(ja)
*
|
2010-04-13 |
2016-05-18 |
ノバルティス アーゲー |
がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ
|
CN106198656B
(zh)
|
2010-08-18 |
2018-12-11 |
生命科技股份有限公司 |
用于电化学检测装置的微孔的化学涂层
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
SI2632467T1
(sl)
*
|
2010-10-25 |
2016-10-28 |
G1 Therapeutics, Inc. |
Inhibitorji CDK
|
AR083797A1
(es)
*
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
SG191844A1
(en)
*
|
2011-01-04 |
2013-08-30 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
US20140113909A1
(en)
*
|
2011-07-01 |
2014-04-24 |
Novartis Ag |
Combination Therapy
|
ES2676180T3
(es)
|
2011-07-01 |
2018-07-17 |
Novartis Ag |
Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
EP3216792B1
(en)
*
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
CA2870019C
(en)
*
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
JP6155332B2
(ja)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
US9388199B2
(en)
|
2012-06-28 |
2016-07-12 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
CN104640855B
(zh)
|
2012-06-28 |
2017-08-29 |
诺华股份有限公司 |
补体途经调节剂及其用途
|
JP6154897B2
(ja)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
ES2710491T3
(es)
|
2012-06-28 |
2019-04-25 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
EA201590200A1
(ru)
|
2012-07-12 |
2015-08-31 |
Новартис Аг |
Модуляторы пути активации комплемента и их применение
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
WO2014022830A2
(en)
|
2012-08-03 |
2014-02-06 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
EP2934515B1
(en)
|
2012-12-20 |
2018-04-04 |
Novartis AG |
A pharmaceutical combination comprising binimetinib
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
WO2014130932A2
(en)
|
2013-02-25 |
2014-08-28 |
Novartis Ag |
Novel androgen receptor mutation
|
BR112015021549A2
(pt)
|
2013-03-13 |
2017-07-18 |
Abbvie Inc |
inibidores de piridina cinase cdk9
|
AU2014244263A1
(en)
*
|
2013-03-13 |
2015-08-13 |
Abbvie Inc. |
CDK9 kinase inhibitors
|
JP2016512560A
(ja)
*
|
2013-03-14 |
2016-04-28 |
アッヴィ・インコーポレイテッド |
ピロロピリミジン系cdk9キナーゼ阻害薬
|
WO2014151444A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
|
AU2014231567A1
(en)
|
2013-03-14 |
2015-10-01 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
|
CN105407889B
(zh)
|
2013-03-15 |
2018-06-01 |
G1治疗公司 |
针对Rb阳性异常细胞增殖的HSPC节制性治疗
|
JP6435315B2
(ja)
*
|
2013-03-15 |
2018-12-05 |
ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. |
高活性抗新生物薬及び抗増殖剤
|
US20140274896A1
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
SG10201906270VA
(en)
|
2013-03-21 |
2019-08-27 |
Novartis Ag |
Combination therapy comprising a b-raf inhibitor and a second inhibitor
|
WO2014172479A1
(en)
|
2013-04-16 |
2014-10-23 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for cdk4 inhibitors
|
BR112016002465B1
(pt)
|
2013-08-14 |
2022-09-20 |
Novartis Ag |
Combinação farmacêutica e seu uso
|
CN106029099A
(zh)
*
|
2013-08-28 |
2016-10-12 |
诺华股份有限公司 |
用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
TW201605857A
(zh)
*
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Cdk8之醫療性抑制劑及其用途
|
US20160257688A1
(en)
*
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
US20160375024A1
(en)
|
2013-11-27 |
2016-12-29 |
Novartis Ag |
Combination therapy comprising an inhibitor of jak, cdk, and pim
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
JP6678584B2
(ja)
*
|
2013-12-20 |
2020-04-22 |
バイオメッド バレー ディスカバリーズ,インコーポレイティド |
Cdk阻害剤およびerk阻害剤の組み合わせを使用するがん処置
|
CN105848682A
(zh)
*
|
2013-12-23 |
2016-08-10 |
诺华股份有限公司 |
药物组合
|
CA2931073C
(en)
*
|
2013-12-23 |
2021-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
WO2015101293A1
(zh)
*
|
2013-12-31 |
2015-07-09 |
山东轩竹医药科技有限公司 |
激酶抑制剂及其用途
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
AU2015240465B2
(en)
|
2014-04-04 |
2020-02-27 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
CN110372720B
(zh)
*
|
2014-05-28 |
2021-03-05 |
锦州奥鸿药业有限责任公司 |
一类激酶抑制剂
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
US9993551B2
(en)
|
2014-09-13 |
2018-06-12 |
Novartis Ag |
Combination therapies of EGFR inhibitors
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CA3000633C
(en)
|
2014-10-14 |
2023-10-03 |
The Regents Of The University Of California |
Use of cdk9 and brd4 inhibitors to inhibit inflammation
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
EP4183806A3
(en)
|
2014-11-12 |
2023-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
EP3231805B1
(en)
*
|
2014-12-12 |
2020-03-04 |
Crystal Pharmatech Co. Ltd. |
Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
|
WO2016126889A1
(en)
*
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|
MY190404A
(en)
|
2015-03-10 |
2022-04-21 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
EP3273959A1
(en)
*
|
2015-03-25 |
2018-01-31 |
Novartis Ag |
Pharmaceutical combinations
|
BR112017021283A2
(pt)
|
2015-04-16 |
2018-06-26 |
Novartis Ag |
comprimido de ribociclib
|
CN106146515B
(zh)
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
TWI696617B
(zh)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
EP3305785B1
(en)
|
2015-05-29 |
2021-08-25 |
Teijin Pharma Limited |
Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
CN105037236B
(zh)
*
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
US20190365741A1
(en)
|
2015-08-28 |
2019-12-05 |
Novartis Ag |
Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
|
ES2761885T3
(es)
|
2015-08-28 |
2020-05-21 |
Novartis Ag |
Combinaciones farmacéuticas que comprenden (a) el inhibidor de la cinasa dependiente de ciclina 4/6 (CDK4/6) LEE011 (= ribociclib) y (b) el inhibidor del receptor del factor de crecimiento epidérmico (EGFR) erlotinib, para el tratamiento o la prevención del cáncer
|
US20180250302A1
(en)
|
2015-08-28 |
2018-09-06 |
Giordano Caponigro |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
CN108348514A
(zh)
|
2015-08-28 |
2018-07-31 |
诺华股份有限公司 |
含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
BR112018008904A2
(pt)
|
2015-11-03 |
2018-11-27 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a tim-3 e seus usos
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
WO2017161253A1
(en)
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
TWI772291B
(zh)
|
2016-03-25 |
2022-08-01 |
大陸商正大天晴藥業集團股份有限公司 |
取代的吡咯並嘧啶類cdk抑制劑、包含其藥物組合物及其用途
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
US10865204B2
(en)
|
2016-04-22 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
|
MX2018013573A
(es)
|
2016-05-07 |
2019-08-01 |
Shanghai Fochon Pharmaceutical Co Ltd |
Ciertos inhibidores de la proteína cinasa.
|
WO2017211245A1
(zh)
*
|
2016-06-06 |
2017-12-14 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
SG10202110874TA
(en)
|
2016-06-07 |
2021-11-29 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
CN109789143A
(zh)
|
2016-07-01 |
2019-05-21 |
G1治疗公司 |
基于嘧啶的抗增殖剂
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
BR112018077155A2
(pt)
|
2016-07-01 |
2019-04-02 |
G1 Therapeutics, Inc. |
processo para preparar um composto, e, composto
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
US20190175598A1
(en)
|
2016-08-23 |
2019-06-13 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of hepatocellular carcinoma
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP3528812B1
(en)
|
2016-10-20 |
2020-12-30 |
Pfizer Inc |
Palbociclib for treating pah
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
WO2018089518A1
(en)
|
2016-11-08 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
CN110177553A
(zh)
*
|
2016-11-17 |
2019-08-27 |
北卡罗来纳大学教堂山分校 |
烷基吡咯并嘧啶类似物及其制备和使用方法
|
TWI799399B
(zh)
|
2016-11-28 |
2023-04-21 |
日商帝人製藥股份有限公司 |
吡啶并〔3,4-d〕嘧啶衍生物及其藥學上所容許之鹽
|
CA3041854A1
(en)
|
2016-11-28 |
2018-05-31 |
Teijin Pharma Limited |
Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
|
CN110035759A
(zh)
|
2016-12-05 |
2019-07-19 |
G1治疗公司 |
化疗方案期间免疫反应的保持
|
CN110177554B
(zh)
|
2017-01-06 |
2023-06-02 |
G1治疗公司 |
用于治疗癌症的组合疗法
|
JP2020506904A
(ja)
*
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ,インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
US11083722B2
(en)
|
2017-03-16 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
EA201992253A1
(ru)
|
2017-03-23 |
2020-03-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
TW201906818A
(zh)
|
2017-05-31 |
2019-02-16 |
美商511製藥公司 |
新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
CN110913861B
(zh)
|
2017-06-29 |
2024-01-09 |
G1治疗公司 |
G1t38的形态学形式及其制造方法
|
US20200155566A1
(en)
|
2017-08-03 |
2020-05-21 |
Novartis Ag |
Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
|
EP3672968B1
(en)
|
2017-08-25 |
2023-11-01 |
Assia Chemical Industries Ltd |
Solid state form of ribociclib succinate
|
US20230160016A1
(en)
|
2017-08-31 |
2023-05-25 |
Novartis Ag |
Methods of selecting a treatment for cancer patients
|
WO2019062854A1
(zh)
*
|
2017-09-29 |
2019-04-04 |
杭州领业医药科技有限公司 |
瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
|
AU2018354972B2
(en)
*
|
2017-10-27 |
2021-07-08 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of ribociclib and its salts
|
JP2021503478A
(ja)
|
2017-11-16 |
2021-02-12 |
ノバルティス アーゲー |
組み合わせ治療
|
US11179365B2
(en)
|
2017-11-16 |
2021-11-23 |
Novartis Ag |
Pharmaceutical combination comprising LSZ102 and ribociclib
|
US11667651B2
(en)
|
2017-12-22 |
2023-06-06 |
Hibercell, Inc. |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
US11111250B2
(en)
|
2017-12-22 |
2021-09-07 |
Shilpa Meicare Limited |
Polymorphs of Ribociclib mono succinate
|
WO2019133864A1
(en)
|
2017-12-29 |
2019-07-04 |
Accutar Biotechnology |
DUAL INHIBITORS OF PARP1 and CDK
|
BR112020013915A2
(pt)
|
2018-01-08 |
2020-12-01 |
G1 Therapeutics, Inc. |
regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
SG11202006748RA
(en)
*
|
2018-01-29 |
2020-08-28 |
Beta Pharma Inc |
2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
|
KR20200131246A
(ko)
|
2018-02-15 |
2020-11-23 |
누베이션 바이오 인크. |
키나제 억제제로서의 헤테로시클릭 화합물
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
CA3043066A1
(en)
|
2018-05-14 |
2019-11-14 |
Apotex Inc. |
Processes for the preparation of ribociclib and intermediates thereof
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
EP3840756A4
(en)
|
2018-08-24 |
2022-04-27 |
G1 Therapeutics, Inc. |
IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
|
AU2019338032A1
(en)
*
|
2018-09-13 |
2021-05-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
CA3117556A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
EP3873608A1
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
US20220056037A1
(en)
*
|
2018-12-28 |
2022-02-24 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
EP3902805A4
(en)
*
|
2018-12-28 |
2023-03-01 |
SPV Therapeutics Inc. |
CYCLIN DEPENDENT KINASE INHIBITORS
|
EP3914353A1
(en)
|
2019-01-23 |
2021-12-01 |
Novartis AG |
New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
|
CN113382731A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和瑞博西尼的药物组合
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
JP2022532918A
(ja)
|
2019-05-20 |
2022-07-20 |
ノバルティス アーゲー |
Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
US20220324837A1
(en)
*
|
2019-06-04 |
2022-10-13 |
Step Pharma S.A.S. |
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
JP2022553832A
(ja)
*
|
2019-11-07 |
2022-12-26 |
クリネティックス ファーマシューティカルズ,インク. |
メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
|
BR112022011758A2
(pt)
*
|
2019-12-16 |
2022-08-30 |
Lunella Biotech Inc |
Terapêutica de câncer inibidor de cdk4/6 seletivo
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
WO2021133886A1
(en)
|
2019-12-23 |
2021-07-01 |
Accutar Biotechnology |
Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
|
EP4126244A4
(en)
*
|
2020-03-27 |
2024-03-27 |
Jiangsu Alphamab Biopharmaceuticals Co Ltd |
COMBINATION OF ANTI-HER2 ANTIBODIES AND CDK INHIBITORS FOR TUMOR TREATMENT
|
WO2021227904A1
(zh)
*
|
2020-05-12 |
2021-11-18 |
苏州阿尔脉生物科技有限公司 |
一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
|
EP4149472A1
(en)
|
2020-05-12 |
2023-03-22 |
Novartis AG |
Therapeutic combinations comprising a craf inhibitor
|
US20230219961A1
(en)
*
|
2020-05-12 |
2023-07-13 |
Suzhou Alphama Biotechnology Co., Ltd. |
Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
|
EP4153597A1
(en)
|
2020-05-19 |
2023-03-29 |
G1 Therapeutics, Inc. |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
JP2023553808A
(ja)
|
2020-11-24 |
2023-12-26 |
ノバルティス アーゲー |
Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
|
EP4251648A2
(en)
|
2020-11-24 |
2023-10-04 |
Novartis AG |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
WO2022169780A1
(en)
|
2021-02-02 |
2022-08-11 |
Les Laboratoires Servier |
Selective bcl-xl protac compounds and methods of use
|
WO2022207788A2
(en)
|
2021-04-01 |
2022-10-06 |
Krka, D.D., Novo Mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022234409A1
(en)
|
2021-05-05 |
2022-11-10 |
Novartis Ag |
Compounds and compositions for the treatment of mpnst
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
US20230022525A1
(en)
|
2021-07-26 |
2023-01-26 |
Celcuity Inc. |
Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
|
WO2023008885A1
(ko)
*
|
2021-07-27 |
2023-02-02 |
보로노이바이오 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
TW202329977A
(zh)
|
2022-01-25 |
2023-08-01 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
WO2023196518A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
WO2023196517A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2023225336A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|